Focus- related epilepsies
The author: Professor Yasser Metwally
INTRODUCTION
It was stated that a spike focus does not necessarily denote a stable epileptogenic focus; benign Rolandic epilepsy stands as the epitome of the truth of this statement. Zones of cortical hyperexcitability (hyperirritability) may behave like a focus in the EEG, but these dysfunctions may burn themselves out with advancing age. Not so an epileptogenic focus which is based on cerebral pathology. Most of this pathology is residual, while the possibility of a space-occupying lesion must always be kept in mind. But are residual epileptogenic lesions quiet residues of a bygone active disease? Modern electromicroscopic work has shown that “residual” gliosis is a very active process, which provides a better understanding for the epileptic irritation of neurons. In this chapter we will discuss the electroclinical criteria of some focal epilepsies.
TEMPORAL LOBE EPILEPSY
-
Introductory Remarks
The temporal lobe is far more often than any other areas the seat of an epileptogenic focus. What renders the temporal lobe so prone to harbor epileptogenic foci? The answer probably lies in 1) special anatomo-physiological properties of the limbic (arche- and palcocortical) portion of the temporal lobe, and 2) a certain vulnerability of neocortical and limbic parts of the temporal lobe to some forms of pathology.
Seizures arising from the temporal lobe have captivated the interest of epileptologists, electroencephalographers, neurologists, neurosurgeons, and even psychiatrists during the past decades. The impressive multitude of temporal lobe functions in the human are reflected by the enormous variety of seizure patterns. Temporal lobe functions are in part higher cortical functions; they are also functions of the limbic system with its crossroads of autonomic nervous system regulations and emotionality.
-
Terminology
The term “temporal lobe epilepsy” is correct as far as “seizures arising from the temporal lobe” are concerned. It should not be used as a synonym for psychomotor (complex partial) seizures, since 1) not all seizure manifestations of the temporal lobe fall into this category (many patients also have grand mal seizures and a few have grand mal only) and 2) psychomotor (complex partial) seizures may occasionally originate from the vicinity of the temporal lobe, usually as extensions of the limbic system into the fronto-orbital region. The reader will find more information and details on the historical development in the section on types of psychomotor seizures.
-
Clinical Ictal Manifestations
The wide variety of seizure manifestations is presented in the section on types of psychomotor seizures.
-
Ictal EEG Manifestations
See the section on types of psychomotor seizures.
-
Interictal EEG Manifestations
The anterior temporal spike or, more often, sharp wave discharge, randomly firing, is the classical EEG finding in the interseizure interval. With the use of the International Electrode System, this discharge is recorded from the F7, or F8, electrode, which is essentially frontobasal and slightly in front of the tip of the temporal lobe. Sleep EEG studies are highly important in demonstrating anterior temporal spiking otherwise anterior temporal spiking might be missed in a tracing obtained solely in the waking state.
The spike (sharp wave) discharge is bilateral in about 25 to 35% of the cases. Patients with bilateral anterior temporal spikes (sharp waves) are more likely to have both psychomotor and grand mal seizures. Sleep has an important role in the facilitation of temporal spikes.
Bilateral anterior temporal spiking may be bilateral independent or synchronous. Bilateral synchrony has been divided into real synchrony and discharges transmitted from one side to the other. The spike discharge occurs over one temporal lobe only in 34%, while transmission from side to side is noted in 24%, synchrony in 19%, and bilateral independence in 23%.
Brain tumor is rarely discovered in patients with bilateral independent temporal spikes. Patients with unilateral spikes often prove to have mesial temporal sclerosis; the superior aspects of the temporal lobe showed a maximum of corticographic spike activity. Patients with lesions of the basomesial surface and the tip of the temporal lobe revealed spikes transmitted secondarily to the opposite side or bilateral synchronous spiking. These patients may show less prominent or even equivocal scalp EEG findings.
The paroxysmal EEG abnormalities may exceed the boundaries of the temporal lobe. Psychomotor or complex partial seizures are more likely to occur when focal EEG abnormalities are limited to the temporal lobe.
In some patients, anterior temporal spikes are scanty, while consistent focal slowing is present over this area. This pattern is usually not good evidence for a space-occupying lesion unless progression of the focal slow (mainly polymorphic delta) activity is demonstrable.
Children and young adolescents with temporal lobe epilepsy and unequivocal complex partial seizures often have inconclusive EEG findings. Spikes or sharp waves may be over midtemporal or central regions (thus falsely suggestive of benign Rolandic epilepsy) or diffuse. Even generalized spike wave discharges may occur and slow spike wave complexes may overshadow all other abnormalities when one deals with a case of Lennox-Gastaut syndrome giving rise to psychomotor seizures.
It evidently takes a while until the classical anterior temporal spike (sharp wave) focus is fully developed. Very rarely, the opposite happens with anterior temporal spiking being just a form of benign midtemporal spiking (even without any seizures and with full EEG normalization at age 11 yr). With advancing age, the anterior temporal spike focus increasingly becomes the impressive hallmark of temporal epilepsy, until an overabundance of this discharge occurs. Above age 50-60 yr, the anterior temporal spike or sharp wave is, in most cases, a simple exaggeration of temporal minor sharp activity, which is extremely common in elderly patients with mild or moderate degrees of cerebrovascular disorder and no seizure disorder whatsoever. In epileptics above age 50, temporal lobe spiking is a very common finding, but this does not necessarily mean that one is dealing with a temporal lobe epileptic; on the contrary, grand mal seizures outnumber psychomotor seizures by a wide margin.
The combination of total absence of paroxysmal discharges, marked unilateral temporal polymorphic delta activity, and recent onset of psychomotor seizures is very suggestive of a rapidly growing temporal lobe tumor. Very slowly growing tumors such as certain astrocytomas may show EEG patterns undistinguishable from those of temporal lobe epileptics with mesial temporal sclerosis. Meningiomas of the medial sphenoid wing position and psychomotor seizures may have very little or no EEG abnormality.
Small sharp spikes (see chapter on abnormal paroxysmal patterns) may appear over the temporal region and its neighborhood in early sleep as forerunners of typical large anterior temporal sharp waves, giving support to the diagnosis of temporal lobe epilepsy. The occurrence of small sharp spikes alone, however, contributes nothing to this diagnosis. These small discharges arise from a wide region, including deep structures and might indicate only some degree of neuronal hyperexcitability.
An unusual EEG pattern in temporal lobe epileptics might take the form frontal midline theta activity with an average frequency of 5.78/sec in 36% of these patients.
Table 1 Electroclinical characteristic of temporal lobe epilepsy.
|
Unfortunately, it must be conceded that a fair number of patients with unequivocal psychomotor (complex partial) seizures show normal EEG tracings awake, asleep, and with activations, not only once but repeatedly. The availability of a CT scan, MRI is particularly important, since certain deep seated tumors impinging on the medial portions of the temporal lobe may give rise to seizures without inter-ictal EEG abnormalities. Sleep deprivation may occasionally bring the EEG abnormalities into the open. A sharp reduction of anticonvulsants usually has a remarkable effect, but, as a conscientious physician, one uses this form of activation with great reservation and reluctance. The epileptic rebound may lead to more widespread or even generalized seizure discharges, thus masking the focal character of the seizure disorder, or, much worse, the patient will have numerous seizures; worst of all, a dreadful status epilepticus grand mal may develop.
The addition of nasopharyngeal leads improves very slightly the chances of demonstrating a temporal lobe epileptogenic focus. In addition to the artifact-proneness of these leads, the electrodes may easily cross over to the side contralateral to the nostril of insertion. Sphenoidal leads are more likely to yield valuable additional information from the anterior portion of the temporal lobe; the invasive character of their insertion has discouraged most electroencephalographers from using these electrodes.
-
Age and Prevalence
Temporal lobe epilepsy spans a period from early childhood to senility but, as was pointed out, classical cases are usually found in older adolescents and in young and middle-aged adults; childhood and senium tend to dilute the clinical and EEG semiology.
-
Psychological and Psychiatric Features
A review of the copious literature on this subject could fill a monograph; in this context, we have to confine ourselves to a few basic statements. According to personal impression, the most common psychological features are irritability and hyposexuality; these data were derived from patients considered candidates for temporal lobectomy because of the severity of their seizure disorder.
A constant state of irritability renders these patients more volatile; some of them exhibit hostility and are prone to aggressive acts, but it must be stated very clearly that these cases are exceptional and not the rule. In recent decades, the conjunction of acts of violence or crime and temporal lobe epilepsy has been widely accepted without sufficient support from clinical data. Single observations of aggressive acts must be considered exceptional. Studies of large patient groups have clearly shown the rarity of aggressive acts in patients with temporal lobe epilepsy. Hyposexuality has been confirmed in these patients.
Patients with major psychomotor epilepsy are subject to an increased risk of psychiatric disturbance but that, except the immediate postictal psychotic state, the risk appears to reflect the site and extent of brain damage and the individual’s psychosocial history and opportunities more than a diagnosis of epilepsy.” This author also feels that “. . . temporal lobe epilepsy makes a very small contribution to the pool of psychiatric disturbances, including violence.”
Relationships to the schizoid personality have been frequently reported and combination with overt schizophrenia is well known, though not common.
The electroencephalographer will occasionally find that patients with temporal lobe epilepsy and schizophrenia show marked EEG improvement or completely normal tracings when the psychiatric condition is at its worst, while the patient is practically seizure-free, and vice versa (enhanced seizure disorder, massive spiking and psychiatric improvement). This “seesaw phenomenon” has been observed (“forced normalization”).
A comparison of left- and right-sided temporal epilepsies (dominant versus nondominant temporal lobe) has shown some psychological-psychiatric differences. Epileptogenic foci in the temporal lobe in the dominant hemisphere are more likely to be associated with aggressive behavior.
The causes of temporal lobe epilepsy are as follows (in order of frequency)
-
No histopathological abnormality, the most common
-
Unspecified minor abnormalities
-
Cortical neuronal loss and gliosis
-
Gliomas and ganglioglioma
-
Cortical neuronal loss, gliosis and hippocampal sclerosis
-
Meningo-cerebral cicatrix and remote contusion
-
Vascular formation of brain and/or pia
-
Hamartomas
-
Tumors other than gliomas
-
Residuum of brain abscess
-
Post-meningitic cerebral atrophy
-
Tuberous sclerosis and formes frustes
-
Subacute and chronic encephalitides
-
Ulegyria
-
Anomalous cases
-
Residuum of old infarct
The higher incidence of tumors deserves special attention when one considers their progressive and eventually life threatening nature. A sizeable portion of these tumors, however, are of very mildly progressive nature and almost behave like a nontumoral lesion. Small tumors as the cause of seizures are found mainly in the mesio-inferior areas such as an uncus and amygdaloid region. Temporal lobe seizures may also be caused by a pituitary tumor with a large supradiaphragmatic portion and, furthermore, by lipomas of the corpus callosum.
-
Neurophysiological Mechanisms
Limbic and neocortical portions of the temporal lobe (and, not seldom, of the adjacent fronto-orbital region) are actively involved in the ictal and inter-ictal epileptic phenomena of temporal lobe epilepsy. The uncinate region, comprising the amygdaloid complex, uncinate gyrus, and anterior-insular and peninsular portions of the temporal lobe, appears to be mostly involved in typical psychomotor automatisms, whereas the lateral temporal neocortex appears to be most active in experienced psychomotor seizures.
The role of the hippocampus remains enigmatic. Hippocampic electrical stimulation in man almost never results in afterdischarges or seizures this structure is more likely to be secondarily involved. Its role …… “to consolidate memory traces”, is often jeopardized in ictal activity. It must be added that the left and right hippocampus apparently serve special memory functions, with verbal memory on the dominant and nonverbal visual memory on the nondominant side. Amygdalo-hypothalamic connections are likely to account for emotional responses, in normal physiology as well as, in a morbid and exaggerated form, during ictal activity. Connections between amygdala and basal ganglia (putamen, globus pallidus, putamen) might serve the behavioral-motor component of temporal lobe seizures. Autonomic manifestations are probably served by the amygdala through the hypothalamus or originate from the insular cortex. Bilateral temporal lobe involvement is very common.
-
Course and Therapy
Until a few years ago, 4 principal medications were used for partial seizures: phenytoin, carbamazepine, valproate, and phenobarbital. In recent years, a number of newer medications have been approved by the FDA. These newer AEDs have not been evaluated in double-blind trials as monotherapy, so how they compare to the older AEDs is not known. The initial choice of medication depends on side-effect profile, cost considerations, and dosage schedule. The major VA trials did not show any significant difference in seizure control among the 4 older AEDs. Adverse effects were greater with phenobarbital and with valproate.
Single-drug therapy is the goal, and the dosage of each medication prescribed should be increased until either seizures are controlled or adverse effects occur.
|
Drug Name |
Carbamazepine (Tegretol, Carbatrol, Epitol)- Affects sodium channels during sustained rapid repetitive firing. Extended release form preferred (Tegretol XR or Carbatrol) because of bid dosing, which improves compliance and leads to more stable blood levels. No IV formulation available. |
|
Adult Dose |
600-2000 mg/d PO |
|
Pediatric Dose |
5 mg/kg/d initially, followed by maintenance dose of 15-20 mg/kg/d |
|
Contraindications |
Documented hypersensitivity; concurrent MAOIs |
|
Interactions |
Danazol may increase serum levels significantly within 30 days (avoid whenever possible); do not coadminister with MAOIs; cimetidine may increase toxicity, especially if taken in first 4 wk of therapy; may decrease primidone and phenobarbital levels (their coadministration may increase carbamazepine levels) |
|
Pregnancy |
D – Unsafe in pregnancy |
|
Precautions |
Do not use to relieve minor aches or pains; caution with increased intraocular pressure; obtain CBCs and serum iron baseline prior to treatment, during first 2 months, and yearly or every other year thereafter; can cause drowsiness, dizziness, and blurred vision; caution while driving or performing other tasks requiring alertness |
|
Drug Name |
Phenytoin (Dilantin)- One of oldest drugs known for treatment of seizures; extremely cost-effective. In young women, can coarsen facial features, cause hirsutism and gingival hyperplasia. In addition, requires frequent blood levels because of nonlinear pharmacokinetics. Long-term use associated with peripheral neuropathy and osteopenia. Can be mixed only with isotonic saline since D5W causes phenytoin to precipitate. Fosphenytoin (prodrug of phenytoin) measured in units of phenytoin equivalents (PE). Fosphenytoin can be diluted with either saline or D5W. |
|
Adult Dose |
Loading dose: 15-20 mg/kg/d PO/IV at rate no faster than 50 mg/min Maintenance: 3-5 mg/kg/d PO/IV Fosphenytoin loading dose: 20 mg PE/kg infused at maximal rate of 150 mg/min |
|
Pediatric Dose |
Initial dose: 5-7 mg/kg/d PO/IV Maintenance: 5-7 mg/kg/d PO/IV |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
Amiodarone, benzodiazepines, chloramphenicol, cimetidine, fluconazole, isoniazid, metronidazole, miconazole, phenylbutazone, succinimides, sulfonamides, omeprazole, phenacemide, disulfiram, ethanol (acute ingestion), trimethoprim, and valproic acid may increase toxicity Barbiturates, diazoxide, ethanol (chronic ingestion), rifampin, antacids, charcoal, carbamazepine, theophylline, and sucralfate may decrease effects May decrease effects of acetaminophen, corticosteroids, dicumarol, disopyramide, doxycycline, estrogens, haloperidol, amiodarone, carbamazepine, cardiac glycosides, quinidine, theophylline, methadone, metyrapone, mexiletine, oral contraceptives, valproic acid |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Perform blood counts and urinalyses when therapy is begun and at monthly intervals for several months thereafter to monitor for blood dyscrasias; discontinue use if skin rash appears and do not resume use if rash is exfoliative, bullous, or purpuric; rapid IV infusion may result in death from cardiac arrest, marked by QRS widening; caution in acute intermittent porphyria and diabetes (may elevate blood glucose); discontinue use if hepatic dysfunction occurs |
|
Drug Name |
Valproate (Depacon, Depakene, Depakote)- Anticonvulsant effective for most seizure types, believed to exert anticonvulsant effect by increasing GABA levels in brain. Approved for monotherapy or adjunctive therapy for partial seizures and generalized tonic-clonic seizures. Depakene capsule or syrup, Depakote tablet or sprinkle. |
|
Adult Dose |
10-15 mg/kg/d IV initially at rate of 20 mg/min; increase by 5-20 mg/kg/wk to maximum 60 mg/kg/d or as tolerated |
|
Pediatric Dose |
20 mg/kg/d initially followed by maintenance dose of 20-40 mg/kg/d |
|
Contraindications |
Documented hypersensitivity; hepatic disease/dysfunction |
|
Interactions |
Cimetidine, salicylates, felbamate, and erythromycin may increase toxicity; rifampin may significantly reduce levels; in children, salicylates decrease protein binding and metabolism; may result in variable changes of carbamazepine concentration with possible loss of seizure control; may increase diazepam and ethosuximide toxicity (monitor closely); may increase phenobarbital and phenytoin levels, while either may decrease valproate levels; may displace warfarin from protein-binding sites (monitor coagulation tests); may increase zidovudine levels in HIV-seropositive patients |
|
Pregnancy |
D – Unsafe in pregnancy |
|
Precautions |
Thrombocytopenia and abnormal coagulation parameters have occurred; risk of thrombocytopenia increases significantly at total trough valproate plasma concentrations 110 mcg/mL in females and 135 mcg/mL in males; at periodic intervals and prior to surgery, determine platelet counts and bleeding time before initiating therapy; reduce dose or discontinue therapy if hemorrhage, bruising, or hemostasis/coagulation disorder occurs; hyperammonemia may occur, resulting in hepatotoxicity; monitor patients closely for appearance of malaise, weakness, facial edema, anorexia, jaundice, and vomiting; may cause drowsiness |
|
Drug Name |
Phenobarbital (Barbita, Luminal, Solfoton)- One of first major AEDs, introduced in 1919. FDA approved for initial or adjunctive therapy for partial-onset seizures. Has major cognitive adverse effects, which has limited its use in favor of newer AEDs that have better side-effect profiles. |
|
Adult Dose |
90 mg PO qd initially; increase by 30 mg/d every mo to usual maintenance dose of 90-120 mg/d |
|
Pediatric Dose |
3-5 mg/kg/d PO initially, followed by maintenance dose of 3-5 mg/kg/d |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
May decrease effects of chloramphenicol, digoxin, corticosteroids, carbamazepine, theophylline, verapamil, metronidazole, and anticoagulants (patients stabilized on anticoagulants may require dosage adjustments if added to or withdrawn from their regimen); alcohol may produce additive CNS effects and death; chloramphenicol, valproic acid, and MAOIs may increase toxicity; rifampin may decrease effects; induction of microsomal enzymes may result in decreased effects of oral contraceptives in women (must use additional contraceptive methods to prevent unwanted pregnancy; menstrual irregularities may also occur) |
|
Pregnancy |
D – Unsafe in pregnancy |
|
Precautions |
In prolonged therapy, evaluate hematopoietic, renal, hepatic, and other organ systems; caution in fever, hyperthyroidism, diabetes mellitus, and severe anemia since adverse reactions can occur; caution in myasthenia gravis and myxedema |
|
Drug Name |
Lamotrigine (Lamictal)- Newer AED approved as adjunctive therapy and cross-over monotherapy for partial seizures. Also blocks sodium channels during sustained rapid repetitive neuronal firing. FDA approved for children younger than 16 years only for Lennox-Gastaut syndrome; not FDA approved for children with partial seizures because of increased incidence of rash. |
|
Adult Dose |
Weeks 1 and 2: 50 mg/d PO; if given as adjunctive therapy with valproic acid, then 25 mg qod Weeks 3 and 4: 100 mg/d PO in divided doses; if given as adjunctive therapy with valproic acid, then 25 mg/d, increase by 100 mg/d PO every wk; if coadministered with valproic acid, increase by 25-50 mg PO every other wk Maintenance dose: 300-500 mg/d PO in divided doses; if coadministered with valproic acid, 100-200 mg/d |
|
Pediatric Dose |
Initial dose: 1-2 mg/kg PO Maintenance dose: 5-10 mg/kg PO |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
Acetaminophen increases renal clearance, decreasing effects; similarly, phenobarbital and phenytoin increase metabolism, decreasing levels; valproic acid increases half-life |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Incidence of severe rash is 1% in pediatric and 0.3% in adult patients; almost all cases occur within 2-8 wk of treatment Incidence of rashes of all types is 3.3% in monotherapy and with adjunctive therapy with enzyme-inducing AEDs (eg, phenytoin, carbamazepine); with enzyme-inhibiting AEDS (eg, valproate), incidence of rash is 10%; risk of rash reduced with slow titration |
|
Drug Name |
Gabapentin (Neurontin)- Approved by FDA as adjunctive therapy for partial seizures. Structurally related to GABA; however, mechanism of action unknown. |
|
Adult Dose |
Start at 300 or 400 mg PO tid and increase prn not to exceed 4800 mg/d Usual minimum effective dose for partial seizures as an adjunct is 1200 mg; if CrCl 30-60 mL/min, 300 mg PO bid; if CrCl 15-30 mL/min, 300 mg PO qd Hemodialysis patients: 200-300 mg after every hemodialysis |
|
Pediatric Dose |
4-13 mg/kg/d PO initially Maintenance: 10-50 mg/kg/d PO |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
Antacids may reduce bioavailability significantly (administer at least 2 h following antacids); may increase norethindrone levels significantly |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Caution in severe renal disease; dizziness or somnolence may occur when starting therapy, so patients should be warned not to drive or operate heavy machinery during initial phase of treatment |
|
Drug Name |
Topiramate (Topamax)- Approved by FDA as adjunctive therapy for partial seizures. Exerts action by 4 mechanisms: sodium channel blockade, enhancement of GABA activity, antagonism of AMPA/kainate-type glutamate excitatory receptors, and weak inhibition of carbonic anhydrase. |
|
Adult Dose |
400 mg PO qd in 2 divided doses; initial starting dose 25 mg/d with gradual increase of 25 mg/wk Therapeutic response may be observed at dose of 200 mg/d; if renal CrCl <70 mL/min, then reduce dose by half> |
|
Pediatric Dose |
1-9 mg/kg/d PO |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
Phenytoin, carbamazepine, and valproic acid can significantly decrease levels; reduces digoxin and norethindrone levels; carbonic anhydrase inhibitors may increase risk of renal stone formation and should be avoided; use with extreme caution when administering concurrently with CNS depressants since may have additive effect in CNS depression, as well as other cognitive or neuropsychiatric adverse events |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
1.5% of patients develop kidney stones, because it is weak carbonic anhydrase inhibitor and reduces urinary citrate excretion while increasing urine pH (more common in males) |
|
Drug Name |
Tiagabine (Gabitril)- Enhances GABA activity by inhibiting uptake in neurons and astrocytes. Can be used as add-on therapy for partial seizures. |
|
Adult Dose |
4 mg PO qd to start, increase by 4-8 mg/d every wk to maintenance dose of 32-56 mg in 2-4 divided doses |
|
Pediatric Dose |
Not established |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
Cleared more rapidly in patients treated with carbamazepine, phenytoin, primidone, or phenobarbital than in patients who have not received one of these drugs |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Patients receiving valproate monotherapy may require lower doses or slower dose titration for clinical response; has caused moderately severe to incapacitating generalized weakness in as many as 1% of patients with epilepsy; weakness may resolve after reduction in dose or discontinuation of tiagabine; should be withdrawn slowly to reduce potential for increased seizure frequency |
|
Drug Name |
Zonisamide (Zonegran)- Has been studied extensively in Japanese and European trials. Blocks T-type calcium currents and prolongs sodium-channel inactivation. Also weak carbonic anhydrase inhibitor. In monotherapy has long half-life of 70 h. |
|
Adult Dose |
100 mg PO qd initially for 2 wk, then increase by 100 mg/d every wk to every 2 wk to maintenance dose of 100-300 mg bid |
|
Pediatric Dose |
Not established |
|
Contraindications |
Documented hypersensitivity; history of urolithiasis |
|
Interactions |
May increase serum carbamazepine levels; carbamazepine may increase concentrations; phenobarbital may decrease levels |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Administration associated with 2-3.5% risk of urolithiasis; anorexia, nausea, ataxia, impaired concentration, and other cognitive side effects have been reported; cleared by hepatic conjugation and oxidation; therefore, dose should be reduced in patients with hepatic insufficiency |
|
Drug Name |
Oxcarbazepine (Trileptal)- Approved by FDA as monotherapy and adjunctive therapy for partial epilepsy in adults and children aged 4-16 years. Blocks sodium-activated channels during sustained rapid repetitive firing. Has no antiepileptic activity itself; its 10-monohydroxy metabolite is active compound. |
|
Adult Dose |
300 mg PO initially bid; increase by 300 mg bid every wk to maintenance of 600-1200 mg bid |
|
Pediatric Dose |
Not established |
|
Contraindications |
Documented hypersensitivity; hypersensitivity to carbamazepine (25-30% have cross-sensitivity) |
|
Interactions |
May decrease levels of dihydropyridine calcium antagonists and oral contraceptives; can reduce serum concentrations of carbamazepine, phenobarbital, phenytoin, and valproic acid; when given in doses 1200 mg/d, may increase phenytoin and phenobarbital serum concentrations significantly; can reduce serum concentrations of oral contraceptives and make oral contraceptives ineffective; can increase clearance of felodipine |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Among persons with hypersensitivity to carbamazepine, 25-30% will have hypersensitivity to oxcarbazepine; can cause cognitive adverse effects such as psychomotor slowing, impaired concentration, impaired speech and impaired language; in persons with impaired renal function (CrCl <30 mL/min), dose should begin at half usual starting dose, and dose increments should be made more slowly; can cause hyponatremia (sodium><125 mmol/L); rapid withdrawal can cause exacerbation of seizures; observe for adverse effects and monitor plasma levels of concomitant anticonvulsants during dose titration> |
|
Drug Name |
Levetiracetam (Keppra)- Approved by FDA in 1999 as add-on therapy for partial seizures. Mechanism of action unknown. Has favorable adverse-effect profile, with no life-threatening toxicity reported to this date. |
|
Adult Dose |
500 mg PO bid initially; increase by 500 mg PO bid every 2 wk; not to exceed 1500 mg PO bid in adults; lower doses recommended in elderly (start at 250 mg PO bid) and in patients with renal impairment |
|
Pediatric Dose |
Not established |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
None reported |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Renally excreted (67%) and, thus, dose should be lowered in renal impairment; major side effects include somnolence, asthenia, incoordination, mild leukopenia (3%), and behavioral changes such as anxiety, hostility, emotional lability, depression and psychosis (1-2%), and depersonalization |
|
Drug Name |
Felbamate (Felbatol)- Approved for medically refractory partial seizures and Lennox-Gastaut syndrome. Has multiple mechanisms of action, including blockade of glycine site of NMDA receptor, potentiation of GABAergic activity, and inhibition of voltage-sensitive sodium channels. |
|
Adult Dose |
600 mg PO tid initially; increase by 600-1200 mg/d every wk; not to exceed 1200-1600 mg PO tid |
|
Pediatric Dose |
Not established |
|
Contraindications |
Documented hypersensitivity; blood dyscrasias; hepatic dysfunction |
|
Interactions |
May increase steady-state phenytoin levels—40% dose-reduction of phenytoin may be necessary in some patients; phenytoin may double clearance, resulting in more than 45% decrease in steady-state levels; phenobarbital may cause increase in phenobarbital plasma concentrations; phenobarbital may reduce plasma levels; may decrease steady-state carbamazepine levels and increase steady-state carbamazepine metabolite levels; may increase steady-state valproic acid levels |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Associated with marked increase in incidence of aplastic anemia (monitor CBC periodically); marked increase in fatal hepatic failure reported in patients receiving felbamate; perform liver function testing (ALT, AST, bilirubin) before therapy and at 1- to 2-wk intervals during therapy; discontinue immediately if liver abnormalities detected during treatment |
Temporal lobe epilepsy is a serious seizure disorder. Good therapeutic responses to first line medications are the exception rather than the rule.
It is saddening to see a large number of patients remain unresponsive to any medication. These patients are candidates for surgical treatment by temporal lobectomy. The facilities for seizure surgery are limited and the selection of patients is beset with psychological problems. Not every suitable candidate is sufficiently motivated to give his consent for this operation. In well screened material, about 40% of the patients will become seizure-free after temporal lobectomy.
The electroencephalographer is often amazed at the minor effects of temporal lobectomy on the EEG as such; such changes are often limited to local voltage depression corresponding to the cortical removal. The excision of this sizeable portion of brain tissue usually produces less EEG effect than a diagnostic cortical biopsy, which is often followed by marked local delta activity for a period of time. Persisting seizure discharges are likely to change their spatial distribution to some extent; previous anterior temporal spike activity may move to the midtemporal region.
FRONTAL LOBE EPILEPSY
-
Introduction
Frontal lobe epilepsy is much less common than temporal lobe epilepsy. Moreover, frontal lobe epilepsy is less significant as an epileptological entity. Frontal lobe seizures often consist of immediate grand mal attacks, thus obscuring any focal initiation, has been widely confirmed.
-
Seven different clinical seizure patterns are distinguished:
1. Immediate unconsciousness followed by a grand mal with minimal or no lateralizing signs.
2. Immediate unconsciousness associated with initial turning of the head and eyes (sometimes of the body) to the opposite side, promptly followed by a grand mal, probably originating from the anterior third or fourth of the frontal lobe contralateral to the adversive movement.
3. Initial adversion of head and eyes to the opposite side, preserved consciousness, and conscious adversive (contraversive) attack which, after 5 to 20 sec may or may not be followed by a grand mal. The origin usually lies in the convexity of the intermediate frontal region.
4. Posturing movement of the body with tonic elevation of the contralateral arm, downward extension of the ipsilateral arm, and turning of head away from the side of the lesion as if looking at the raised hand. This type of seizure arises from the medial aspect of the intermediate frontal region in the vicinity of the supplementary motor region. This type of seizure has also been described as “mesiofrontal epilepsy”and was attributed to the supplementary motor region within the interhemispheric fissure.
5. Brief attacks of “dizziness,” a “flush,” or “weak” feeling. This vague sensation may stop after a few seconds or it may be followed by brief arrest of activity, confusion, and staring. This attack imitates the petit mal absence clinically and even electroencephalographically. In contrast with true petit mal absences, these attacks may be followed by a grand mal.
6. Sudden alteration of thought processes, such as “forced thinking” (“my thoughts suddenly became fixed”). This may be followed by a petit mal-like absence or by a grand mal.
7. Seizures arising from the fronto-orbital cortex are practically undistinguishable from temporal lobe epilepsy. Petit mal absence status-like ictal symptomatology due to a left frontal epileptogenic focus is occasionally demonstrated.
-
More frequently occurring seizure manifestations are listed in the following table.
Table 2. Subdivision of Frontal Lobe Seizures.
|
More Frequent |
Less Frequent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
EEG Observations
Frontal lobe spiking may be found in various forms. Spike activity is particularly scarce and the search for an EEG focus often elusive in mesiofrontal (interhemispheric) foci. If demonstrable at all, spikes are found over the superior frontal or frontal midline region; their size is small.
Large and somewhat blunted sharp waves are found in cases of presumed fronto- orbital epilepsy. Generalized synchronous spike wave bursts are found in patients with bilateral synchrony. In some of the cases, only depth EEG can demonstrate the primary focus. The ictal patterns of frontal lobe epilepsy are not basically different from other forms of neocortical focal seizure disorders.
-
Course and Therapy
Anticonvulsants indicated for use in partial seizures are the medical treatment of choice. Patients will generally require many years of treatment, so consideration of side effects is important. While most of the anticonvulsants are in pregnancy category C or D, the risk of medication to the fetus must be weighed against the risk of maternal seizures to the fetus. Due to the risk of level fluctuations, patients should not switch between brand and generic anticonvulsants, and if a generic is used, patients should receive the same generic formulation consistently.
|
Drug Name |
Carbamazepine (Tegretol, Tegretol XR, Carbatrol)- First-line agent for partial seizures with or without secondary generalization; particularly effective in the treatment of nocturnal motor/dystonic frontal lobe seizures; potential hematologic and other adverse effects; blood monitoring is recommended. Available as tablets, extended release tablets, extended release capsules, and suspension. Patients who are not using extended release form often require tid dosing. |
|
Adult Dose |
200 mg PO qd or bid, initially; increase by 200 mg weekly as needed; maximal recommended dose is 1200 mg/d in divided doses; although higher doses may be required in patients on other enzyme-inducing drugs |
|
Pediatric Dose |
Small children frequently require suspension <6 years: 10-20 mg/kg/d bid or tid for tab, qid for suspension; increase as needed up to 35 mg/kg/d in divided doses 6-12 years: 100 mg bid or half tsp qid; increase as needed by 100 mg/d, up to a maximum of 1000 mg/d in divided doses |
|
Contraindications |
Documented hypersensitivity; history of bone marrow depression; administration of MAO inhibitors within last 14 d |
|
Interactions |
Serum levels may increase significantly within 30 days of danazol coadministration (avoid whenever possible); do not coadminister with monoamine oxidase (MAO) inhibitors; cimetidine may increase toxicity especially if taken in first 4 wk of therapy; carbamazepine may decrease primidone, and phenobarbital levels (their coadministration may increase carbamazepine levels) |
|
Pregnancy |
D – Unsafe in pregnancy |
|
Precautions |
Do not use to relief minor aches or pains; caution with increased intraocular pressure; obtain CBCs and serum-iron baseline prior to treatment, during first 2 months, and yearly or every other year thereafter; can cause drowsiness, dizziness, and blurred vision; caution while driving or performing other tasks requiring alertness |
|
Drug Name |
Phenytoin (Dilantin Kapseals, Dilantin Infatabs)- Available as tablets, capsules, infatabs, and suspension. A first-line agent for partial seizures; advantage of phenytoin — quickly achieves therapeutic level and the possibility of once daily dosing (Dilantin Kapseals), which increases compliance. |
|
Adult Dose |
Some patients will require oral loading, in order to obtain a therapeutic level quickly. Phenytoin can be loaded as 1 g divided in 3 doses (400-300-300) at 2 hour intervals; maintenance dose of 300 mg/d should be started 24 h after loading; if patients are not to be loaded, initiate dosing at 300 mg/d, either as tid, bid, or qd; further dosage increase should be based on response to treatment; due to zero order kinetics, increase by 30 mg or 50 mg IV administration should be reserved for situations such as status epilepticus or for patients with IV access only; IV loading dose is 15-20 mg/kg; fosphenytoin is more expensive than IV phenytoin, but does not cause tissue necrosis or irritation when extravasated, and may be given IM |
|
Pediatric Dose |
<6 years: Initiate at 5 mg/kg/d in 2-3 divided doses; maintenance is 4-8 mg/kg >6 years: May require adult dosing |
|
Contraindications |
Documented hypersensitivity; sino-atrial block, second and third degree AV block, sinus bradycardia, or Adams-Stokes syndrome |
|
Interactions |
Amiodarone, benzodiazepines, chloramphenicol, cimetidine, fluconazole, isoniazid, metronidazole, miconazole, phenylbutazone, succinimides, sulfonamides, omeprazole, phenacemide, disulfiram, ethanol (acute ingestion), trimethoprim, and valproic acid may increase phenytoin toxicity Phenytoin effects may decrease when taken concurrently with barbiturates, diazoxide, ethanol (chronic ingestion), rifampin, antacids, charcoal, carbamazepine, theophylline, and sucralfate Phenytoin may decrease effects of acetaminophen, corticosteroids, dicumarol, disopyramide, doxycycline, estrogens, haloperidol, amiodarone, carbamazepine, cardiac glycosides, quinidine, theophylline, methadone, metyrapone, mexiletine, oral contraceptives, valproic acid |
|
Pregnancy |
D – Unsafe in pregnancy |
|
Precautions |
Perform blood counts and urinalyses when therapy is begun and at monthly intervals for several months thereafter to monitor for blood dyscrasias; discontinue use if a skin rash appears and do not resume use if rash is exfoliative, bullous or purpuric; rapid IV infusion may result in death from cardiac arrest, marked by QRS widening; caution in acute intermittent porphyria and diabetes (may elevate blood sugars; discontinue use if hepatic dysfunction occurs |
|
Drug Name |
Valproic acid, divalproex sodium (Depakote, Depakene, Depacon)- Available as tablets, capsules, syrup, sprinkles, injection. Although valproate is considered a first-line agent for the treatment of primary generalized epilepsy, it is indicated for partial seizures as well, particularly for patients with secondary generalization. Must be used cautiously in women of childbearing age; has limited use in young children due to the risk of hepatic failure, which may be fatal. |
|
Adult Dose |
10-15 mg/kg/d PO in divided doses, and increase by 5-10 mg/kg/wk; usual maximum dose is 60 mg/kg/d Alternatively, 20 mg/min IV 60-min infusion; faster rates have been used |
|
Pediatric Dose |
<2 years: Not established; risk of hepatic failure >2 years: Administer as in adults |
|
Contraindications |
Documented hypersensitivity; hepatic disease/dysfunction |
|
Interactions |
Coadministration with cimetidine, salicylates, felbamate, and erythromycin may increase toxicity; rifampin may significantly reduce valproate levels; in pediatric patients, protein binding and metabolism of valproate decrease when taken concomitantly with salicylates; coadministration with carbamazepine may result in variable changes of carbamazepine concentrations with possible loss of seizure control; valproate may increase diazepam and ethosuximide toxicity (monitor closely); valproate may increase phenobarbital and phenytoin levels while either one may decrease valproate levels; valproate may displace warfarin from protein binding sites (monitor coagulation tests); may increase zidovudine levels in HIV seropositive patients |
|
Pregnancy |
D – Unsafe in pregnancy |
|
Precautions |
Thrombocytopenia and abnormal coagulation parameters have occurred; the risk of thrombocytopenia increases significantly at total trough valproate plasma concentrations > 110 mcg/mL in females and 135 mcg/mL in males; at periodic intervals and prior to surgery determine platelet counts and bleeding time before initiating therapy; reduce dose or discontinue therapy if hemorrhage, bruising or a hemostasis/coagulation disorder occur; hyperammonemia may occur, resulting in hepatotoxicity; monitor patients closely for appearance of malaise, weakness, facial edema, anorexia, jaundice, and vomiting; may cause drowsiness |
|
Drug Name |
Gabapentin (Neurontin)- Indicated for use in partial seizures with and without secondary generalization; has relatively few drug interactions and side effects. |
|
Adult Dose |
300 mg bid or tid; may be increased weekly up to 1800-2400 mg/d in divided doses; some patients require doses up to 3600 mg/d or higher; renally excreted, dosage adjustment necessary for patients with renal dysfunction |
|
Pediatric Dose |
<12 years: Not established >12 years: Administer as in adults |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
Antacids may significantly reduce bioavailability of gabapentin (administer at least 2 h following antacids); may increase norethindrone levels significantly |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Caution in severe renal disease |
|
Drug Name |
Lamotrigine (Lamictal)- Newer agent, effective for partial seizures with or without secondary generalization. Main side effect of concern is rash, which may be severe. |
|
Adult Dose |
Dosing depends on coadministration of other anticonvulsants, specifically valproate; see dosing instructions for specific guidelines; slow titration is recommended to prevent the occurrence of rash |
|
Pediatric Dose |
Not established |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
Acetaminophen increases renal clearance of medication, decreasing effects; similarly, phenobarbital and phenytoin increase lamotrigine metabolism causing a decrease in lamotrigine levels; administration of valproic acid with lamotrigine increases half-life |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Serious or life-threatening rash, more likely in pediatric patients and patients on valproate While many other side effects reported, all are infrequent or rare |
|
Drug Name |
Levetiracetam (Keppra)- Newer agent, effective for partial seizures with or without secondary generalization. Few side effects, no drug-drug interactions. Does not require blood monitoring, although there are reports of slight decreases in red and white blood cell counts. |
|
Adult Dose |
500 mg bid increase an additional 1000 mg/d in divided dosing every two weeks to a maximum recommended daily dosage of 3000 mg; slower titration may be better tolerated by some patients; no IV form available; requires adjustment for impaired renal function |
|
Pediatric Dose |
Not established |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
None reported |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Somnolence, coordination abnormalities, and behavioral abnormalities may occur; requires adjustment for impaired renal function |
|
Drug Name |
Oxcarbazepine (Trileptal)- Indicated as monotherapy or adjunctive therapy in the treatment of partial seizures with or without secondary generalization. Mechanism of action similar to carbamazepine, without metabolism to an epoxide. Active metabolite MHD (monohydroxy derivative). If patient is being converted from carbamazepine to oxcarbazepine, the inducing effect of carbamazepine on cytochrome P450 enzymes will be reduced, and other AEDs may need adjustment. No IV form available. If added to phenytoin, may elevate phenytoin levels by up to 20%. |
|
Adult Dose |
Monotherapy: 150 mg or 300 mg bid initially; dose may be increased by 300 mg/d q3d; maximum recommended daily dose of 1200-2400 mg in divided dosing; elderly patients may require slower titrations |
|
Pediatric Dose |
Approved for use as adjunctive therapy in pediatric patients age 4-16 Initiate at 8-10 mg/kg, generally not to exceed 600 mg/d in divided dosing; target dose is based on weight 20-29 kg: 900 mg/d 29-39 kg: 1200 mg/d >39 kg: 1800 mg/d |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
Increases phenytoin level; may interact with oral contraceptives, calcium channel blockers |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Hyponatremia may be clinically significant with Na <125; serum sodium measurement recommended; somnolence, concentration difficulty, ataxia |
|
Drug Name |
Topiramate (Topamax)- Indicated for adjunctive treatment of partial seizures with or without secondary generalization, and for tonic-clonic seizures. Approved for adults and for children ages 2-16. Has multiple mechanisms of action. |
|
Adult Dose |
25-50 mg/d for 1 wk, then increase by 25-50 mg/d/wk in bid dosing to therapeutic dose of 200-400 mg/d |
|
Pediatric Dose |
1-3 mg/kg/d for 1 wk, then increase by 1-3 mg/kg/d every 1-2 wks to target dose of 5-9 mg/kg/d taken bid |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
Phenytoin, carbamazepine and valproic acid can significantly decrease topiramate levels; topiramate reduces digoxin and norethindrone levels, when administered concomitantly; concomitant use with carbonic anhydrase inhibitors may increase risk of renal stone formation and should be avoided; use topiramate with extreme caution when administering concurrently with CNS depressants since may have an additive effect in CNS depression, as well as other cognitive or neuropsychiatric adverse events |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Risk of developing a kidney stone formation is increased 2-4 times that of untreated population; risk may be reduced by increasing fluid intake; caution in renal or hepatic impairment |
|
Drug Name |
Zonisamide (Zonegran)- Indicated for adjunctive treatment of partial seizures with or without secondary generalization. There is evidence that it is effective in myoclonic and other generalized seizure types as well. |
|
Adult Dose |
100 mg/d for 2-wk, then increase by 100 mg/d q2wk to maximum of 400 mg/d; may be given qd or bid |
|
Pediatric Dose |
Not established |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
May increase serum carbamazepine levels; carbamazepine may increase zonisamide concentrations; phenobarbital may decrease zonisamide levels |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
May cause drowsiness, weight loss, ataxia, nausea, and slowing of mental activity |
|
Drug Name |
Tiagabine (Gabitril)- Indicated for adjunctive treatment of partial seizures with or without secondary generalization. Mechanism of action in antiseizure unknown. Believed to be related to ability to enhance activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the CNS. |
|
Adult Dose |
Begin at 4 mg/d for 1 wk, increase by 4-8 mg/d per week to maximum of 56 mg/d in 2-4 daily doses |
|
Pediatric Dose |
Not established |
|
Contraindications |
Documented hypersensitivity |
|
Interactions |
Cleared more rapidly in patients treated with carbamazepine, phenytoin, primidone, and phenobarbital than in patients who have not received these drugs |
|
Pregnancy |
C – Safety for use during pregnancy has not been established. |
|
Precautions |
Patients receiving valproate monotherapy may require lower doses or a slower dose titration of tiagabine for clinical response; moderately severe to incapacitating generalized weakness has been reported following administration of tiagabine in up to 1% of patients with epilepsy; weakness may resolve after a reduction in dose or discontinuation of tiagabine; tiagabine should be withdrawn slowly to reduce potential for increased seizure frequency |
ROLANDIC (SENSORIMOTOR) EPILEPSY
-
Introductory Remarks
This subsection essentially pertains to Rolandic epilepsies of adult life; benign Rolandic epilepsy of childhood and rare cases of progressive Rolandic epilepsy in children have been presented in the chapter on age-determined epileptic conditions.
Focal motor seizures arising from the pre-central motor region have been well known. These seizures beautifully reflect the somatotopic arrangement of the motor cortex. Jackson (1870) made a clear distinction between seizures starting with twitching of facial and glossal muscles and those starting with finger, hand, or foot movements of the opposite side.
The somatotopic arrangement of the motor cortex must not be conceived of as a mosaic in which the smallest focus of epileptic irritation will give rise to contralateral twitching of extremely small corresponding muscular segments. In other words, there does not seem to be full equality among the cortical segments. Areas with a large cortical-Rolandic representation also have low thresholds for electrical stimulation (index finger, thumb, then face and foot). This is probably also true for the less commonly focal sensory seizures arising from the post-central gyrus.
-
Clinical-ictal Manifestations
Clonic twitching of contralateral muscle segments with preserved consciousness is the principal manifestation of Cortical motor Rolandic epilepsy. This clonic activity may a) remain localized, b) spread over the rest of the contralateral half of the body, and c) eventually culminate in a grand mal seizure. The spread of clonic activity from one body region to another is widely known as “Jacksonian march”.
Focal Rolandic motor seizures usually last from 10 see to several minutes. Attacks exceeding a duration of 30 min must be regarded as a focal motor status or even as epilepsia partialis continua or Koshevnikov syndrome. Most attacks started in the hand, followed by mouth, arm, fingers, foot, face, and leg. Involvement of trunk muscles was uncommon.
As to epileptic manifestations of the sensory Rolandic cortex (post-central gurus), a variety of paresthesias or dysesthesias have been observed. “Formication,” or the sensation of running ants, is the most common symptom, followed by numbness, pain, and sensations of heat or cold. Pain as a sensoricortical ictal symptom is more common than one would expect from experimental data concerning pain perception and the post-central gyrus.
Focal motor or sensory attacks can stop at any stage. Sensory focal attacks are usually quickly associated with focal motor activity. Uncontaminated sensory cortical seizures are so rare that one should thoroughly rule out possibilities such as ischemic cerebral attacks or peripheral neuritic pain.
Bilateral focal motor seizures are extremely rare. In such cases, the clonic motions spread from one side gradually to the other half of the body.
Post-epileptic paralysis (Todd’s paralysis) has been known since the original observations of Todd (1856). Post-ictal paresis of the ictally involved muscle segments has been thought to be caused by metabolic exhaustion but, in recent years, the concept of active inhibition has prevailed. Postictal motor deficits are more common in active pathology such as vascular lesions, AV malformations, or tumors. In general, these motor deficits are more common in children and last for minutes, hours, or a few days.
-
EEG Findings
The ictal EEG shows astounding variations. Lack of ictal EEG changes is a well known weakness of electroencephalography, probably due to the smallness of the cortical spiking. In the majority of the cases, ictal repetitive spiking is present over the affected motor cortex. Interictal spike activity also shows variations ranging from absence to pronounced focal spiking, which, incidentally, is most common in children with benign Rolandic epilepsy. In patients with acute watershed-type infarctions, focal motor seizures are often accompanied by PLED.
-
Neurophysiological Considerations
Focal motor seizures are usually strictly cortical, but the structural lesion causing the seizures may not be precisely located in the Rolandic region. Neighboring lesions may cause the pre-central cortex to erupt in epileptic discharges due to its low threshold.
-
Etiology
Onset of focal motor or focal sensory seizures in adult life must always raise the suspicion of a tumor involving or in the vicinity of the Rolandic cortex. Arteriovenous malformations should also be considered one of the more common causes of focal motor seizures. Post-traumatic epilepsy and cerebral arteriosclerosis are also common causes; neurosyphilis and tuberculoma previously ranked high in the list of causes.
-
Prevalence
Prevalence is probably between 3 and 10% of a population of epileptics, depending on the sampling.
-
Therapy and Course
Therapy and course depend strongly on the type of underlying pathology. In general, focal motor and sensory seizures show a good to very good response to first line anticonvulsants. Surgical interventions are limited by the threat of subsequent catastrophic motor deficits. Removal of parasagittal meningiomas is usually followed by excellent results.
PARIETAL LOBE EPILEPSY
Epileptic phenomena of parietal origin do not form a well defined epileptological entity. Parietal lobe functions are complex; functional differences between the dominant and the nondominant parietal lobe compound the problems of parietal lobe function.
There is, therefore, no typical parietal lobe seizure symptomatology. In most cases, the seizures affect visual functions and a variety of complex visual disturbances may be found, such as scintillation or oscillopsia. Short attacks of extremely severe vertigo may occur. Automatisms and ictal tonic postural changes of the upper limbs is reported as parietal lobe phenomena.
Trauma is the most common cause of these seizures. Post-traumatic epilepsy caused by lacerating wounds from high velocity projectiles and shell fragments most often affects the centroparietal region.
OCCIPITAL LOBE EPILEPSY
Epileptic phenomena of the occipital lobe are not common. When the attacks originate from the calcarine fissure, elementary visual sensations such as bright light, sparks, or a ball of fire are experienced. The sensations may move across the visual field or remain stationary for the duration of the seizure. Spread from a temporal lobe focus into the occipital region with elementary visual ictal sensations has been reported.
Attacks of blindness may be accompanied by generalized spike wave activity. Bilateral synchronous occipital spike wave activity has been reported during visual hallucinations. Epileptic nystagmus, also called oculocionic seizures, may occur during occipital lobe seizures. It is interesting to note that occipital lobe epilepsy tends to occur in acute or subacute cerebral disorders. Occipital lobe epilepsy must be carefully distinguished from migrainous or ischemic disturbances.
REFERENCES
-
Acharya V, Acharya J, Luders H: Olfactory epileptic auras. Neurology 1998 Jul; 51(1): 56-61.
- Adams RD, Victor M, Ropper AH: Epilepsy and other seizure disorders. Principles of Neurology 1997; 313-343.
- Berkovic SF, McIntosh A, Howell RA: Familial temporal lobe epilepsy: a common disorder identified in twins. Ann Neurol 1996 Aug; 40(2): 227-35.
- Engel J, Williamson PD, Heinz-Gregor W: Mesial Temporal Lobe Epilepsy. Epilepsy: A Comprehensive Textbook 1997; 2417-2426.
- Foldvary N, Nashold B, Mascha E: Seizure outcome after temporal lobectomy for temporal lobe epilepsy: a Kaplan-Meier survival analysis. Neurology 2000 Feb 8; 54(3): 630-4.
- Gibbs EL, Gibbs FA, Fuster B: Psychomotor Epilepsy. Archives of Neurology and Psychiatry 1948; 60: 331-339.
- Gillham R, Kane K, Bryant-Comstock L: A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000 Sep; 9(6): 375-9.
- Harvey AS, Berkovic SF, Wrennall JA: Temporal lobe epilepsy in childhood: clinical, EEG, and neuroimaging findings and syndrome classification in a cohort with new-onset seizures. Neurology 1997 Oct; 49(4): 960-8.
- Harvey AS, Grattan-Smith JD, Desmond PM: Febrile seizures and hippocampal sclerosis: frequent and related findings in intractable temporal lobe epilepsy of childhood. Pediatr Neurol 1995 Apr; 12(3): 201-6.
- Hennessy MJ, Langan Y, Elwes RD: A study of mortality after temporal lobe epilepsy surgery. Neurology 1999 Oct 12; 53(6): 1276-83.
- Jeong SW, Lee SK, Kim KK: Prognostic factors in anterior temporal lobe resections for mesial temporal lobe epilepsy: multivariate analysis. Epilepsia 1999 Dec; 40(12): 1735-9.
- Kim WJ, Park SC, Lee SJ: The prognosis for control of seizures with medications in patients with MRI evidence for mesial temporal sclerosis. Epilepsia 1999 Mar; 40(3): 290-3.
- Luciano D: Partial seizures of frontal and temporal origin. Neurol Clin 1993 Nov; 11(4): 805-22.
- Passaro EA, Beydoun A: Identification of potential candidates for epilepsy surgery. E Medicine Neurology 2001.
- Passaro EA, Beydoun A: The Pre-surgical Evaluation of Medically Refractory Epilepsy. E Medicine Neurology 2001.
- Passaro EA, Beydoun A, Minecan D: Outcome of Epilepsy Surgery. E Medicine Neurology 2001.
- Semah F, Picot MC, Adam C: Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998 Nov; 51(5): 1256-62.
- Spencer DC, Morrell MJ, Risinger MW: The role of the intracarotid amobarbital procedure in evaluation of patients for epilepsy surgery. Epilepsia 2000 Mar; 41(3): 320-5.
- Sperling MR, Feldman H, Kinman J: Seizure control and mortality in epilepsy. Ann Neurol 1999 Jul; 46(1): 45-50.
- Wiebe S, Blume WT, Girvin JP: A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001 Aug 2; 345(5): 311-8.
- Williamson PD, Thadani VM, French JA: Medial temporal lobe epilepsy: videotape analysis of objective clinical seizure characteristics. Epilepsia 1998 Nov; 39(11): 1182-8.
- Winawer MR, Ottman R, Hauser WA: Autosomal dominant partial epilepsy with auditory features: defining the phenotype. Neurology 2000 Jun 13; 54(11): 2173-6.
Leave a Comment
You must be logged in to post a comment.